By combining its technologies, the company brings the benefits of rapid CGP to more labs
Life science manufacturing company Thermo Fisher Scientific has made the Oncomine Comprehensive Assay Plus (OCAP) available on the Ion Torrent Genexus System (Genexus System), helping to accelerate precision oncology research.
“In recent years, new genomic insights have played an essential role in advancing our understanding of human health and driving novel drug development,” said president of Clinical Next Generation Sequencing at Thermo Fisher Scientific Kathy Davy.
“The addition of the OCAP on the Genexus System brings the benefits of rapid CGP to more labs, empowering researchers to leverage more comprehensive results at a much faster pace and accelerate what could be life-saving research.”
The OCAP detects single-nucleotide variants, insertions and deletions, copy number variations, and fusions. The assay also detects genomic signatures such as homologous recombination deficiency (HRD), tumour mutational burden (TMB) and microsatellite instability (MSI).
Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumour mutational burden (TMB) and microsatellite instability (MSI). With the capabilities of the Genexus System, researchers can now detect a broad range of these important biomarkers, quickly and easily.
The Genexus System is an automated and integrated NGS platform capable of delivering NGS results as soon as the next day.
With the OCAP available on the Genexus System, research teams can use the OCAP to detect a range of genomic alterations in 517 genes and deliver genomic profiling (CGP) results within a day. CGP facilitates the simultaneous analysis of various biomarkers in one text to maximise insights efficiently.
